Resources
36 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 3/11/2024 (updated 3/28/2024)
This is a resource for harm reduction programs and communities looking to establish new community advisory boards (CABs) or improve upon existing ones. Syringe Services Program Community Advisory Boards: A Framework offers structured recommendations to develop, convene, and sustain effective syringe service program CABs.
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 6/2/2023 (updated 3/27/2024)
Behavioral health care encompasses a wide variety of interventions delivered by many different types of providers. Although there is a call for expanding direct or indirect behavioral health service systems to care for those affected, in the U.S., nearly all these providers are in short supply.
Posted 5/17/2023 (updated 3/27/2024)
Illuminate Colorado, an RCORP Neonatal Abstinence Syndrome (NAS) grantee, and partners presented on their Tough as a Mother campaign. Tough as a Mother is a statewide campaign launched in May 2020 and has been working to decrease the stigma around maternal substance use disorder. The Illuminate Colorado Team provided an overview of their campaign and how others can access the shared resources, followed by time for Q&A.
Posted 3/21/2023 (updated 3/27/2024)
Researchers at Indiana University conducted one-on-one interviews with clinical providers and other stakeholders in the recovery arena to better understand the slow uptake of the drug most used to treat opioid use disorder. Biases against buprenorphine was the most consistent theme, though the reason for bias differed amongst stakeholders. Clinical providers and behavioral health care providers preferred the abstinence approach rather than use of medications.
Posted 3/7/2023 (updated 3/27/2024)
A new article in RHIhub's The Rural Monitor describes the community's understanding of Native culture in Gallup, New Mexico to take an effective, holistic community-wide approach to recovery of SUD. The article highlights a community-wide consortium that works hard to tackle the issue of alcohol and substance use disorders through withdrawal management, peer counseling, assisting with housing, and other services.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.